> ## Content Index
> Fetch the complete content index at: https://www.sanarelab.science/llms.txt
> Use this file to discover other available public pages before exploring further.

# Metformin Use Linked to Lower Bladder Cancer Risk: Meta-Analysis of 6.3 Million People with Diabetes
- URL: https://www.sanarelab.science/metformin-bladder-cancer-risk-meta-analysis-2026/
- Published: 2026-09-23T02:00:05.000Z
- Updated: 2026-09-23T08:12:27.000Z
- Description: Pooled data from 14 observational studies (~6.3M people with T2DM): metformin associated with lower bladder cancer incidence (RR 0.67, 95% CI 0.46–0.98); pioglitazone and SGLT2 inhibitors showed no significant association.
- Author: Sanare Lab
- Tags: #short-read, News, Research, Repurposed Drugs

Key Takeaway

A PRISMA meta-analysis of 14 observational studies (\~6.3 million people with type 2 diabetes) links metformin use to a one-third lower relative risk of bladder cancer (RR 0.67; 95% CI 0.46–0.98). The evidence is observational — an association, not proof of prevention.

Type 2 diabetes carries an increased bladder-cancer risk, and which glucose-lowering drugs modify that risk has been debated for years. A systematic review by Mathez et al. (Urologia, September 17, 2026) pooled the available observational evidence to answer it.

## The Numbers

Metformin: pooled RR 0.67 (95% CI 0.46–0.98) — significantly lower risk, with substantial between-study heterogeneity. Pioglitazone: RR ≈1.05 (0.52–2.09), I²=99% — no clear association overall. SGLT2 inhibitors: RR 0.98 (0.70–1.37) — no increased-risk signal. For context on how repurposed drugs are dosed in practice, see our [dosing calculator](https://www.sanarelab.science/protocol-dosing-workspace/); background on the [Care Oncology Protocol](https://www.sanarelab.science/care-oncology-protocol-coc/) and on [metformin–ivermectin breast-cancer data](https://www.sanarelab.science/ivermectin-metformin-breast-cancer-autophagy-pi3k-2026/) is available in our long-reads.

## References

1. Mathez W, Vincentelli A, Chaoui I, Bruyère F, Bourgi A. Antidiabetic drug exposure and risk of bladder cancer: A systematic review and meta-analysis. *Urologia*. 2026 Sep 17\. [doi:10.1177/03915603261486088](https://doi.org/10.1177/03915603261486088?ref=sanarelab.science). [PMID: 42755180](https://pubmed.ncbi.nlm.nih.gov/42755180/?ref=sanarelab.science).

## Medical Disclaimer

This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. The study described is a meta-analysis of observational data on cancer risk in people with type 2 diabetes — not a treatment trial, and not a basis for starting, stopping or changing any medication. Always consult a licensed healthcare provider before making decisions about any drug or supplement, especially if you have a medical condition or are undergoing treatment.